Peter Barrett, Ph.D.Peter Barrett is a partner at Atlas Venture and focuses on investments in therapeutics that significantly improve patients’ quality of life. At Atlas, Peter has been involved in the creation of several novel therapeutic and drug discovery platform companies. He is currently chairman of Obsidian Therapeutics, Synlogic, and Zafgen (NASDAQ: ZFGN), Cadent Pharmaceuticals, and also serves on the boards of Luc Therapeutics, InfaCare, and JenaValve. Prior to joining Atlas in 2002, Peter was co-founder, executive vice president, and chief business officer of Celera Genomics. Peter helped launch Celera as a publicly traded entity in 1999. He led Celera’s strategic alliances and acquisitions, and participated in raising nearly $1 billion in capital for the company. Prior to Celera, Peter held senior management positions at PerkinElmer, most recently serving as vice president, corporate planning and business development. During his tenure, he expanded the life science business units through a series of licensing agreements, partnerships, and acquisitions. Peter is currently vice chairman of the advisory council of the Barnett Institute of Chemical and Biological Analysis at Northeastern University, as well as adjunct professor at the Barnett Institute. He also is a member of the research council at Boston Children’s Hospital, and serves on the board of PerkinElmer. Peter received a BS in chemistry from Lowell Technological Institute (now known as the University of Massachusetts, Lowell), and a PhD in analytical chemistry from Northeastern University. He also completed Harvard Business School’s Management Development Program. Outside the office, Peter is a skier, competitive sailor, theater lover, and frustrated actor.
< Back to Board